Loading clinical trials...
Loading clinical trials...
A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma
Conditions
Interventions
Revlimid
Velcade
+2 more
Locations
5
United States
David Geffen School of Medicine at UCLA UCLA
Los Angeles, California, United States
Memorial West Cancer Center Memorial Cancer Institute
Pembroke Pines, Florida, United States
Northside Hospital Central Research Dept.
Atlanta, Georgia, United States
Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists
Omaha, Nebraska, United States
Brooke Army Medical Center Hematology/Oncology
San Antonio, Texas, United States
Start Date
June 14, 2016
Primary Completion Date
May 22, 2017
Completion Date
May 22, 2017
Last Updated
July 24, 2018
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions